FOLEY HOAG LLP for GILEAD SCIENCES INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 - CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL KIM | — |
Medicare/Medicaid MMM
Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV testing, screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Federal program coverage; access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; Implementation of Public Law No: 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL KIM | — |
Pharmacy PHA
Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid and Affordable Care Act implementation; FDA issues and 340B. S. 3056: CREATES Act of 2016.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL KIM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.